Samuel R. Denmeade
Department of Oncology
The Johns Hopkins University School of Medicine
Cancer Research Building I
Rm 1M43
Name/email consistency: high
- Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. Brennen, W.N., Rosen, D.M., Wang, H., Isaacs, J.T., Denmeade, S.R. J. Natl. Cancer Inst. (2012)
- Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Brennen, W.N., Isaacs, J.T., Denmeade, S.R. Mol. Cancer Ther. (2012)
- Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Denmeade, S.R., Isaacs, J.T. Prostate (2010)
- The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. Denmeade, S.R., Isaacs, J.T. Cancer Biol. Ther. (2005)
- Development of prostate cancer treatment: the good news. Denmeade, S.R., Isaacs, J.T. Prostate (2004)
- Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Denmeade, S.R., Sokoll, L.J., Dalrymple, S., Rosen, D.M., Gady, A.M., Bruzek, D., Ricklis, R.M., Isaacs, J.T. Prostate (2003)
- Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. Denmeade, S.R., Litvinov, I., Sokoll, L.J., Lilja, H., Isaacs, J.T. Prostate (2003)
- Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. Denmeade, S.R., Jakobsen, C.M., Janssen, S., Khan, S.R., Garrett, E.S., Lilja, H., Christensen, S.B., Isaacs, J.T. J. Natl. Cancer Inst. (2003)
- A history of prostate cancer treatment. Denmeade, S.R., Isaacs, J.T. Nat. Rev. Cancer (2002)